Effects of iron on cardiovascular, kidney and safety outcomes in patients with chronic kidney disease: a systematic review and meta-analysis

Bernard Chan MD,^{1,2} Amanda Varghese MD,³ Sunil V Badve MBBS PhD,^{4,5} Roberto

Pecoits-Filho MD PhD,⁶ Murilo Guedes MD PhD,⁶ Clare Arnott MBBS PhD,^{4,7} Rebecca

Kozor MBBS PhD,^{1,2} Emma O'Lone MBChB PhD,^{2,3} Min Jun PhD,⁴ Sradha Kotwal

MBChB PhD,^{4,8} Geoffrey A Block MD,⁹ Glenn M. Chertow MD,¹⁰ Scott D Solomon MD,¹¹

Muthiah Vaduganathan MD MPH,¹¹ Brendon L. Neuen MBBS MSc PhD^{3,4,11}

- 1. Department of Cardiology, Royal North Shore Hospital, Sydney, Australia.
- 2. Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
- 3. Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
- 4. The George Institute for Global Health, University of New South Wales, Sydney, Australia.
- 5. Department of Renal Medicine, St George Hospital, Sydney, Australia.
- 6. Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
- 7. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.
- 8. Department of Nephrology, Prince of Wales Hospital, Sydney, Australia.
- 9. US Renal Care, Denver, USA.
- Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, USA.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.

Manuscript type: Original article

Word count: 2,740

Tables and Figures: 1 table, 5 figures

Address for Correspondence:

Dr Brendon Neuen MBBS(Hons) MSc PhD

Renal and Metabolic Division

The George Institute for Global health

Level 18, International Towers 3, 300 Barangaroo Ave, Barangaroo NSW 2000 Australia

Email: <u>bneuen@georgeinstitute.org.au</u>

ABSTRACT

Background and aims

Heart failure and chronic kidney disease (CKD) are closely linked, with iron deficiency being highly prevalent in both conditions. Yet, major cardiovascular and nephrology guidelines offer contrasting recommendations on the use of iron. We evaluated the effects of iron versus usual care/placebo on clinical outcomes in patients with CKD.

Methods

We conducted a systematic review and meta-analysis of randomised trials of intravenous or oral iron in CKD (PROSPERO CRD42023453468). We searched Medline, Embase and the Cochrane Register from database inception until February 1, 2024 to identify eligible trials. We determined results overall and stratified by dialysis- and non-dialysis-requiring CKD using random effects models, with certainty of evidence assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The primary composite endpoint was heart failure hospitalisation or cardiovascular death.

Results

We identified 45 trials that met our inclusion criteria. Compared to usual care/placebo, iron reduced the risk of the primary composite endpoint (1659 events; RR 0.84, 95% CI 0.75-0.94; moderate certainty) an effect consistent across dialysis and non-dialysis requiring CKD (P-heterogeneity=0.70). The effect on the primary endpoint appeared driven by both components of hospitalisation for heart failure (RR 0.77; 95% CI 0.61-0.96; moderate certainty) and cardiovascular death (RR 0.81; 95% CI 0.65-1.02; low certainty). The incidence of serious adverse events was lower for iron compared to usual care/placebo (RR 0.90, 95% CI 0.82-0.98; moderate certainty; P-heterogeneity=0.09).

Conclusion

Iron therapies may reduce the risk of heart failure or cardiovascular death in patients with

CKD. Randomised rials evaluating effects of iron on clinical outcomes are needed, especially

in non-dialysis CKD, with or without anaemia.

Iron is an essential trace element with biologic roles in haemoglobin synthesis, cellular function, and oxygen transport. Approximately one-third of patients with chronic kidney disease (CKD) have relative or absolute iron deficiency(1); both of which are associated with reduced health-related quality of life, cardiovascular events, and death, independent of anaemia.(2, 3) In patients with advanced CKD, iron deficiency and reduced erythropoietin synthesis are key drivers of anaemia. Among patients with kidney failure, iron deficiency and anaemia are virtually ubiquitous, owing to the effects of blood loss and chronic inflammation; chronic inflammation leads to upregulation of hepcidin and diminished intestinal iron absorption as well as sequestration of iron in reticuloendothelial cells.(4) Therefore, in patients with dialysis- and non-dialysis-requiring CKD, iron is frequently administered to manage anaemia and reduce the need for, and/or dosing of, erythropoiesis stimulating agents (ESAs).

In patients with heart failure with reduced ejection fraction who are iron deficient, multiple randomised, placebo-controlled trials have indicated that intravenous iron administration reduces hospitalisation for heart failure and improves functional status and quality of life.(5) As a result, clinical practice guidelines from the European Society of Cardiology and other expert scientific statements recommend intravenous iron to improve functional status and clinical outcomes in patients with heart failure with reduced ejection fraction *independent of anaemia*.(6) In contrast, kidney disease-focused guideline development groups, including Kidney Disease Improving Global Outcomes (KDIGO), recommend screening for iron deficiency only when anaemia develops, and largely focus on iron therapies as a tool *to manage anaemia*, with CKD trials mostly evaluating effects or iron on haemoglobin concentrations and ESA dosing.(7)

Inconsistent recommendations from widely accepted specialty care guidelines are noteworthy since heart failure and CKD frequently coexist, and the presence of one complicates the management of the other.(8, 9) The bi-directional relation between these two conditions suggests that iron might reduce the risk of heart failure and/or other cardiovascular events in patients with CKD. In addition to trials in heart failure that included many patients with CKD, several randomised trials of iron therapies in primary CKD populations have been conducted, comparing iron versus placebo or usual care, newer versus older generation formulations, intravenous versus oral supplementation, and higher versus lower doses of oral iron. To date, these results have not been systematically evaluated or quantitatively synthesised.

We therefore conducted a systematic review and meta-analysis to evaluate the effects of iron therapies on cardiovascular, kidney and safety outcomes in patients with dialysis- and non-dialysis-requiring CKD.

METHODS

We conducted and reported this systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, with prospective registration on PROSPERO (CRD42023453468).

Search strategy and selection criteria

We searched Medline, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) from database inception to February 1, 2024 using search terms including "iron therapies" and related phrases, the names of individual iron compounds, "chronic kidney disease," "heart failure," and terms related to randomised controlled trials. The full search

strategy, including text words and medical subject headings, is provided in the appendix (**Table S1**).

All randomised controlled trials of adults (aged ≥ 18 years) with CKD comparing the effects of intravenous or oral iron, with usual care or placebo, on cardiovascular, kidney and safety outcomes were eligible for inclusion. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.72m² or an albumin-creatinine ratio >30 mg/g. Since the majority of patients with dialysis-requiring CKD receive regular iron administration as part of usual care,(10) we included trials that evaluated different dosing strategies (e.g., proactive versus reactive iron administration) in this population. We also included trials comparing iron-based phosphate binders (i.e., sucroferric oxyhydroxide and ferric citrate coordination complex) versus usual care or placebo. Secondary aims included evaluating cardiovascular, kidney and safety outcomes reported from trials that assessed the effects of (1) newer versus older iron formulations, (2) intravenous versus oral iron, and (3) higher versus lower dose oral iron (outside of dialysis-requiring CKD), where data were available. Multi-arm trials were included by combining two or more arms receiving iron therapies (when the comparison arm was usual care or placebo), or by combining treatment arms based on the generation or dose of the iron therapy (when there was no usual care or placebo arm). Trials that focused on adults who had undergone kidney transplantation were not excluded.

Data extraction

Two authors (BC and AV) independently screened the titles and abstracts of all identified articles and, when indicated, reviewed full-text reports to identify potentially relevant studies. Any disagreements related to the eligibility of studies were discussed and resolved with a third author (BLN). The same two authors independently extracted all data using Covidence

systematic review software 2023 (Veritas Health Innovation, Melbourne, Australia) and assessed risk of bias at the study level using the Cochrane Risk of Bias 2 tool. Additionally, we contacted investigators to request additional unpublished trial data for key outcomes. Any discrepancies in data extraction were also resolved by the third author (BLN).

Outcomes

The primary endpoint was a composite of heart failure hospitalisation and cardiovascular death. Other cardiovascular outcomes included heart failure hospitalisation, cardiovascular death, myocardial infarction (MI) and stroke. Where data were available, we also evaluated the effects of iron therapies on kidney outcomes including change in eGFR, proteinuria and kidney failure requiring dialysis. We also assessed effects on all-cause mortality and serious adverse events.

Data analysis and synthesis

We prespecified that treatment effects on clinical outcomes were to be quantitatively synthesised using a random effects model to obtain summary treatment effect estimates expressed as relative risks with associated 95% confidence intervals (95% CI). Our preference was to use hazard ratios from time-to-first event analyses, but where these were unavailable, we used estimated treatment effects obtained from recurrent events analyses. For treatment comparisons where only the number of events and participants were reported, we calculated and pooled risk ratios to maximise the information obtained from trial-level data.

We summarised effects on eGFR and proteinuria without conducting inference tests because of substantial heterogeneity in how data on these outcomes were reported (some trials reporting values at baseline and follow-up while other trials reported change from baseline in

each treatment arm), as well as imbalances in baseline values between active and control arms.

Because most patients with dialysis-requiring CKD are routinely administered iron to support erythropoiesis,(10) we conducted stratified analyses according to dialysis- and non-dialysisrequiring CKD subgroups. Between-study variation was evaluated based on P heterogeneity values obtained from a random effects model, with standard chi-squared tests for heterogeneity used to assess for differences between dialysis- and non-dialysis-requiring subgroups.

We summarised the certainty of evidence for each outcome using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, based on the following domains: within-study risk of bias, indirectness of evidence, unexplained heterogeneity or inconsistency of results, and imprecision of results.(11)

Statistical analyses were performed using STATA version 17.0.

RESULTS

Our search strategy yielded 2317 records, of which 248 full texts were assessed for eligibility (**Figure S1**). We identified 45 trials that met our inclusion criteria. Overall, 18 and 26 trials enrolled participants with dialysis- and non-dialysis-requiring CKD, respectively, and one trial enrolled participants from both groups. Five trials studied participants who had heart failure with reduced ejection fraction where treatment effects in CKD subgroups were reported.(12-16) There were 26 trials that compared the effects of iron versus placebo or usual care,(12-37) eight trials of intravenous versus oral iron,(38-45) nine trials of newer

versus older iron formulations,(46-54) and two trials of higher versus lower oral iron doses.(55, 56). Ten trials assessed effects on a primary clinical endpoint, while biochemical or surrogate outcomes were the primary focus in 35 trials. Details of trials comparing iron versus usual care or placebo are summarised in **Table 1**, while trials of other treatment comparisons are summarised in **Tables S1-3**.

Risk of bias was low overall in the larger, event-driven trials in patients with dialysisrequiring CKD and heart failure with reduced ejection fraction (**Table S4**). However, there was substantial heterogeneity in risk of bias across other trials and for other comparisons (**Tables S4-S7**).

Overall, randomisation to iron reduced the risk of hospitalisation for heart failure or cardiovascular death by 16% (1658 events; RR 0.84, 95% CI 0.75-0.94; moderate certainty; **Figure 1**) an effect consistent across dialysis- and non-dialysis-requiring CKD subgroups (RR 0.85, 95% CI 0.75-0.96 and RR 0.81, 95% CI 0.64-1.03; P-heterogeneity=0.73). Risk reductions on the primary composite endpoint appeared driven by both components of hospitalisation for heart failure (376 events; RR 0.77; 95% CI 0.61-0.96; moderate certainty; **Figure 2**) and CV death (288 events; RR 0.81; 95% CI 0.65-1.02; low certainty; **Figure 2**), with no evidence of heterogeneity across dialysis- and non-dialysis-requiring CKD subgroups (both P-heterogeneity>0.10) For intravenous versus oral iron and newer versus older iron formulations, no clear differences were observed for these outcomes, although data were limited to a small number of trials (**Figure S1-2**).

In contrast to hospitalisation for heart failure or cardiovascular death, there were fewer myocardial infarction and stroke events recorded in the included trials. Randomisation to iron

reduced the risk of MI (187 events; RR 0.66, 95% CI 0.50-0.88; low certainty; **Figure 3**), driven entirely by the PIVOTAL trial in dialysis-requiring CKD, with few events in other trials. No clear effect on stroke was observed (74 events; RR 0.91, 95% CI 0.58-1.42; very low certainty; **Figure 3**). There were too few data to reliably assess effects on MI or stroke for intravenous versus oral iron and newer versus older iron formulations (**Figures S1-2**).

In patients with non-dialysis-requiring CKD, randomisation to ferric citrate coordination complex reduced the risk of kidney failure based on data from one trial (63 events; RR 0.48, 95% CI 0.32-0.71; very low certainty; **Figure 3**). There were generally no effects on eGFR or proteinuria observed with iron versus usual care or placebo, but heterogeneity in data presentation and imbalances between treatment arms precluded quantitative synthesis (**Table S8-10**). For other comparisons, there were few if any data reported on kidney outcomes (**Figure S2**; **Table S11-15**).

Randomisation to iron reduced the risk of all-cause mortality (765 events; RR 0.85, 95% CI 0.74-0.98; low certainty; **Figure 4**), driven largely again by the PIVOTAL trial in dialysisrequiring CKD, although no statistical evidence of heterogeneity was observed across dialysis- and non-dialysis-requiring CKD subgroups (P-heterogeneity=0.52). Fewer serious adverse events were observed with iron compared to usual care or placebo (2,562 events, RR 0.90, 95% CI 0.82-0.98; moderate certainty; P-heterogeneity across CKD subgroups=0.09; **Figure 5**).

DISCUSSION

In this systematic review and meta-analysis, we observed that iron therapies reduced the risk of hospitalisation for heart failure or cardiovascular death compared to placebo or usual care, with consistent effects in patients with dialysis- and non-dialysis-requiring CKD. Although iron also appeared to reduce the risk of MI, kidney failure, and all-cause mortality, effects were imprecise or uncertain, often driven by a single trial not powered for these endpoints, and with very limited, if any, data in non-dialysis-requiring CKD. For comparisons of intravenous versus oral iron, newer versus older iron formulations, and higher versus lower oral iron doses, the lack of data precluded our ability to draw any reliable inferences about effects on cardiovascular events. Taken together, the data suggest that the provision of iron may yield beneficial cardiovascular effects in patients with CKD, particularly related to heart failure. Given these findings, dedicated clinical trials of intravenous or oral iron in patients with non-dialysis-requiring CKD without heart failure are warranted.

We should emphasise the fact that many of the trials included in our systematic review enrolled patients with heart failure and reduced ejection fraction; yet heart failure with preserved ejection fraction is the predominant form of heart failure in patients with CKD.(57)

In contrast to trials testing the effects of iron administration in heart failure (where we examined results in the CKD subgroup), only a single dedicated CKD trial, PIVOTAL,(58) was designed to evaluate the effects of iron on cardiovascular outcomes, despite these outcomes being consistently identified as a priority for patients and their caregivers.(59) Instead, CKD trials focused almost exclusively on correction of anaemia and changes in ESA dosing. These trials were largely motivated by concerns about ESA safety in non-dialysis-requiring CKD and economic considerations.(60, 61) The reduction in myocardial infarction, driven largely by PIVOTAL, raises the possibility that the cardiovascular benefits of iron in CKD might extend beyond reductions in heart failure and related events. But without

adequately powered cardiovascular outcome trials in patients with non-dialysis CKD, effects on MI or stroke remain uncertain.

There is currently a clear distinction in recommendations between cardiology and nephrology clinical practice guidelines regarding the use of iron therapies. The European Society of Cardiology heart failure guidelines recommends intravenous iron in patients with heart failure with reduced ejection fraction who are iron deficient to improve quality of life (1A recommendation) and to reduce the risk of hospitalisation for heart failure (2A recommendation).(6) In contrast, the KDIGO 2012 guidelines for the management of anaemia in CKD recommend a trial of iron (intravenous or oral) to increase haemoglobin without starting an ESA or to reduce the dose of ESA required to maintain haemoglobin concentrations and mitigate the need for red blood cell transfusions(2C recommendation).(7) However, trials in patients with heart failure with reduced ejection fraction indicate that benefits on heart failure outcomes are *independent* of anaemia.(5)

Our findings suggest that reconsidering current recommendations on the use of iron in CKD might be appropriate and allow more patients to benefit from a therapy with a favourable benefit risk profile. A multinational study of almost 7000 patients across North America, Brazil and Europe identified significant undertreatment of iron deficiency in patients with CKD, even amongst those with anaemia.(1)

The lower incidence of serious adverse events with iron therapies versus usual care or placebo is reassuring, especially in patients with kidney failure where there has previously been concern about increased risk of infection and thrombosis.(62) Small trials, not specifically conducted in CKD, have suggested that newer iron formulations may be superior

to older formulations with respect to safety;(63) however, we found no evidence that serious adverse events differed for intravenous versus oral iron and newer versus older iron formulations. Nevertheless, the overall safety profile of iron supports the feasibility of placebo-controlled outcome trials of iron therapies in CKD designed to evaluate effects on clinical outcomes.

While the available evidence suggests a potential role of iron therapies in reducing risk of worsening heart failure in CKD, this comes with the caveat that almost all the data for this outcome were derived from trials of patients with heart failure with reduced ejection fraction. Thus, it is difficult to disentangle whether these effects are driven by the presence of heart failure with reduced ejection fraction, rather than CKD per se. While there were few available data on kidney outcomes, the finding that ferric citrate coordination complex (compared to usual care) reduced the need for dialysis in a single phase 2 trial raises the possibility that iron therapies may slow the progression of kidney disease, or ameliorate signs or symptoms of uremia (or heart failure) that might prompt dialysis initiation.(64) These data, and the uncertainty they highlight, underscores the need for adequately powered randomised trials evaluating the effects of iron on functional status, health-related quality of life and clinical outcomes, especially in patients with non-dialysis-requiring CKD, with or without anaemia.

This work benefits from a pre-specified, comprehensive and systematic approach to the quantitative synthesis and interpretation of many randomised trials. We evaluated data for multiple treatment comparisons. However, some important limitations should be recognised. This was a two-stage tabular meta-analysis using mostly published data and thus we were not able to assess treatment interactions across important subgroups such as those based on transferrin saturation, serum ferritin or haemoglobin. Outside of the large event-driven

outcome trials, cardiovascular events were generally not independently adjudicated, which may be particularly relevant given the clinical overlap between heart failure and CKD progression. Data for some iron products, such as ferric derisomaltose, were only available for the primary outcome. Limited data for MI, stroke and CKD progression are reflected in imprecise treatment effect estimates and limited our ability to test for heterogeneity across dialysis- and non-dialysis-requiring CKD subgroups. Accepting these limitations, our findings provide the most comprehensive assessment of the therapeutic landscape for iron therapies in CKD and underscores the need for randomised, placebo-controlled outcome trials in patients with CKD, especially those not on dialysis.

In summary, iron therapies may reduce the risk of hospitalisation for heart failure or cardiovascular death in patients with CKD. Randomised trials evaluating effects of iron on clinical outcomes are warranted, especially in non-dialysis CKD, with or without anaemia.

ACKNOWLEDGEMENTS

BLN is supported by an Australian National Health and Medical Research Council Emerging Leader Investigator Grant (grant number 2026621) and a Ramaciotti Foundation Health Investment Grant (grant number 2023HIG69). The funders had no role in the writing of the manuscript or decision to submit for publication.

DISCLOSURES

SVB reports consulting fees from Bayer, AstraZeneca, GSK and Vifor Pharma; speaking fees from Bayer, AstraZeneca, Pfizer and Vifor Pharma (all honoraria paid to his institution); and non-financial research support from Bayer.

RPF is an employee of Arbor Research Collaborative for Health, which receives global support for the ongoing DOPPS Programs (provided without restriction on publications by a variety of funders; for details see https://www.dopps.org/AboutUs/Support.aspx) and has received research grants from Fresenius Medical Care; consulting fees (paid to the employer) from AstraZeneca, Akebia, Novo Nordisk and Fresenius, Bayer, Boehringer, Novo Nordisk and Akebia.

GMC has served on the Board of Directors of Satellite Healthcare, a non-profit dialysis provider. He has served as Chair or Co-Chair of Trial Steering Committees with Akebia, AstraZeneca, CSL Behring, Sanifit, and Vertex. He has served as an Advisor to Applaud, CloudCath, Durect, Eliaz Therapeutics, Miromatrix, Outset, Physiowave, Renibus, and Unicycive. He has served on Data Safety Monitoring Boards with Bayer, Mineralys, and ReCor.

SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly,

Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, US2.AI and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Puretech Health.

MV has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics

BLN has received fees for travel support, advisory boards, scientific presentations and steering committee roles from AstraZeneca, Bayer, Boehringer and Ingelheim, Cambridge Healthcare Research, Cornerstone Medical Education, the Limbic, Janssen, Medscape and Travere with all honoraria paid to The George Institute for Global Health.

All other authors have nothing to disclose.

| Trial | Year | Participants with CKD / Total study population | Duration of Follow- up | Primary Population | Intervention | Comparator | Mean Age | Female (%) | Primary Outcome |
|------------------------|------|---------------------------------------------------------|------------------------------|-----------------------------------------------------------------|---------------------------------------|---------------------------------------------|-------------|------------|--------------------------------------------------------|
| Besarab et al.(18) | 2000 | 42/42 | 6 months | Haemodialysis | IV iron dextran (target TSAT>30%) | IV iron dextran (target TSAT 20- 30%) | 60.8 | 40.5 | ESA dose needed to maintain Hb levels |
| DRIVE(23) | 2007 | 134 / 134 | 6 weeks | Haemodialysis | IV ferric gluconate | Usual care | 59.9 | 49.6 | Change in Hb |
| FAIR-HF(12) | 2009 | 203 / 459 | 24 weeks | HFrEF (NYHA II with LVEF ≤40% or NYHA III with LVEF ≤45%) | IV ferric carboxymaltose | IV saline | 67.7 | 53.2 | Self-reported PGA and NYHA functional class |
| McIntyre et al.(31) | 2009 | 63 / 63 | 5 weeks | Haemodialysis | PO fermagate | PO placebo | 59.1 | 28.6 | Change in serum phosphate |
| Charytan et | 2013 | 97 / 513 | 30 days | Haemodialysis | IV ferric | Usual care | 55.9 | 33.0 | Incidence in treatment- |
| al.(22) | 2015 | 416 / 513 | 50 days | Non-dialysis CKD | carboxymaltose | Usual care | 64.5 | 67.3 | emergent adverse events |
| Yokoyama et al.(36) | 2014 | 90 / 90 | 8 weeks | Non-dialysis CKD | PO ferric citrate | PO placebo | 65.1 | 41.9 | Change in serum phosphate |
| Block et al.(21) | 2015 | 149 / 149 | 12 weeks | Non-dialysis CKD | PO ferric citrate | PO placebo | 65.0 | 66.0 | Change in TSAT and serum phosphate |
| CONFIRM- HF(16) | 2015 | 105 / 304 | 52 weeks | HFrEF≤45% | IV ferric carboxymaltose | IV saline | 69.2 | 46.8 | Change in 6MWT distance |
| CRUISE 1 and 2(25) | 2015 | 599 / 599 | 48 weeks | Haemodialysis | IV ferric pyrophosphate citrate | IV standard dialysate | 58.4 | 36.4 | Mean change in Hb |
| PRIME(27) | 2015 | 103 / 103 | 9 months | Haemodialysis | IV ferric pyrophosphate citrate | IV standard dialysate | 59.0 | 38.8 | Change in ESA dose to maintain Hb 9.5- 11.5g/dL |
| Floege et al.(26) | 2015 | 644 / 644 | 52 weeks | Haemo- or peritoneal dialysis | PO sucroferric oxyhydroxide | PO sevelamer | 55.4 | 41.5 | Change in serum phosphate |
| Lewis et al.(34) | 2015 | 441 / 441 | 52 weeks | Haemo- or peritoneal dialysis | PO ferric citrate | PO calcium acetate and/or sevelamer | 54.5 | 38.8 | Mean change in serum phosphate |
| Fishbane et al.(24) | 2017 | 233 / 233 | 24 weeks | Non-dialysis CKD | PO ferric citrate | PO placebo | 65.4 | 63.1 | Proportion of patients with Hb rise ≥ 1.0 g/dL |
| Koiwa et al.(29) | 2017 | 213 / 213 | 12 weeks | Haemodialysis | PO sucroferric oxyhydroxide | PO sevelamer | 60.9 | 34.9 | Change in serum phosphate |
| Iguchi et al.(28) | 2018 | 40 / 40 | 12 weeks | Non-dialysis CKD | PO ferric citrate | Usual care | 70.1 | 62.5 | Change in serum ferritin, FGF23 and PTH |
| Block et al.(20) | 2019 | 203 / 203 | 9 months | Non-dialysis CKD (eGFR≤20 ml/min/1.73m ²) | PO ferric citrate | Usual care | 62.4 | 38.0 | Change in Hb, TSAT, phosphate, FGF23 and PTH |

Table 1. Characteristics of trials comparing iron therapies vs. usual care or placebo.

| PIVOTAL(30) | 2019 | 2141/2141 | 2.1 years | Haemodialysis | IV iron sucrose (proactive regimen) | IV iron sucrose (reactive regimen) | 62.8 | 34.7 | Composite of non-fatal myocardial infarction, non-fatal stroke, heart failure hospitalisation or death |
|----------------------------------------|------|-------------|-----------|----------------------|-----------------------------------------------|-----------------------------------------------|------|------|-------------------------------------------------------------------------------------------------------------------------|
| AFFIRM- AHF(15) | 2020 | 580 / 1108 | 52 weeks | HFrEF with LVEF <50% | IV ferric carboxymaltose | IV placebo | 74.5 | 47.2 | Composite of heart failure hospitalisation and cardiovascular death |
| van den Oever et al.(35) | 2020 | 200 / 200 | 13 months | Haemodialysis | IV iron sucrose | Usual care | 68.9 | 31.4 | Median percentage of Hb values in target range (6.8-7.4 mmol/L) |
| Susantitaphong et al.(33) | 2020 | 200 / 200 | 6 months | Haemodialysis | IV iron (ferritin target 600-700 ng/mL) | IV iron (ferritin target 200-400 ng/mL) | 52.9 | 46.5 | Effect on ESA dose (erythropoietin resistance index) |
| AEGIS- CKD(32) | 2021 | 167 / 167 | 52 weeks | Non-dialysis CKD | PO ferric maltol | PO placebo | 67.4 | 70.1 | Change in Hb |
| Zununi Vahed et al.(37) | 2021 | 60 / 60 | 6 months | Haemodialysis | IV iron (high dose) | IV iron (low dose) | 61.2 | 40.0 | ESA dose needed to maintain Hb levels 10-12 g/dL |
| The Iron and the Heart Study(19) | 2021 | 54 / 54 | 3 months | Non-dialysis CKD | IV ferric derisomaltose | IV saline | 59.6 | 51.9 | Change in 6MWT distance |
| IRONMAN(13) | 2022 | 730 / 1137 | 2.7 years | HFrEF with LVEF ≤45% | IV ferric derisomaltose | Usual care | 73.3 | 26.4 | Composite of heart failure hospitalisation and cardiovascular death |
| HEART- FID(14) | 2023 | 1553 / 3065 | 12 months | HFrEF with LVEF ≤40% | IV ferric carboxymaltose | IV placebo | 68.6 | 33.8 | Hierarchical composite of death and heart failure hospitalisation, or change from baseline in 6MWT distance |
| MAINTAIN- IRON(17) | 2023 | 79 / 79 | 12 months | Haemodialysis | IV iron sucrose (high dose) | IV iron sucrose (low-dose) | 70.8 | 55.7 | ESA dose needed to maintain Hb 10-12 g/dL |

IV: intravenous; PO: per oral; TSAT: transferrin saturation; ESA: erythropeotin stimulating agent; Hb: haemoglogbin; HFrEF: heart failure with reduced ejection fraction; LVEF: left ventricular ejection fraction; NHYA: New York Heart Association Class; PGA: patient global assessment; 6MWT: six minute walk test; FGF23: fibroblast growth factor-23; PTH: parathyroid hormone.

Figure 1. Effect of iron therapies vs. usual care or placebo on hospitalisation for heart failure or cardiovascular death in people with CKD.

Trial Active Control RR (95% CI) Non-dialysis CKD FAIR-HF* 8/130 0.60 (0.23, 1.56) 8/73 CONFIRM-HF* 8/24 13/36 0.87 (0.29, 2.59) AFFIRM-AHF 104/292 119/288 0.77 (0.59, 1.01) **IRONMAN*** 248/363 318/367 0.77 (0.60, 0.98) HEART-FID 288/801 278/752 0.94 (0.79, 1.12) Subgroup ($I^2 = 0.0\%$, P-heterogeneity=0.57) 0.85 (0.75, 0.96) **Dialysis-requiring CKD** PIVOTAL 126/1093 140/1048 0.81 (0.64, 1.03) 0.84 (0.75, 0.94) Overall (I² = 0.0%, P-heterogeneity= 0.69) Heterogeneity between groups: P=0.73 **GRADE** certainty of evidence: Moderate 0.25 0.5 2 1 4 Favours iron Favours usual care/placebo

Heart failure hospitalisation or cardiovascular death


*First and recurrent hospitalisation for heart failure or cardiovascular death. CKD: chronic kidney disease; RR: relative risk; CI: confidence interval. GRADE: Grading of Recommendations, Assessment, Development and Evaluation.

Figure 2. Effect of iron therapies on (A) hospitalisation for heart failure and (B) cardiovascular death in people with CKD.

| Trial | Active | Control | RR (95% CI) |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Non-dialysis CKD | | | |
| FAIR-HF | 4/130 | 6/73 | 0.36 (0.10, 1.2 |
| Charytan et al. (non-dialysis) | 4/204 | 3/212 | 1.39 (0.31, 6. |
| Yokoyama et al. | 1/60 | 0/30 | → 1.52 (0.06, 36 |
| Block (2015) & Fishbane et al. (2017) | 27/190 | 23/188 | 1.16 (0.69, 1. |
| AFFIRM-AHF* | 88/292 | 100/288 | 0.79 (0.57, 1. |
| The Iron and the Heart Study | 0/26 | 0/28 | → 1.07 (0.02, 52 |
| Subgroup (I ² = 0.0%, P-heterogeneity=0. | | < | 0.86 (0.66, 1. |
| Dialysis-requiring CKD | | | |
| Koiwa et al. | 2/100 | 0/92 | 4.60 (0.22, 94 |
| PIVOTAL | 42/1093 | 68/1048 - | 0.56 (0.38, 0. |
| Susantitaphong et al. | 2/100 | 3/100 | 0.67 (0.11, 3. |
| MAINTAIN IRON | 2/39 | 1/40 | 2.05 (0.19, 21 |
| Subgroup (I ² = 0.0%, P-heterogeneity=0. | .40) | \diamond | 0.60 (0.42, 0. |
| Overall (I ² = 3.2%, P-heterogeneity= 0 | 41) | \diamond | 0.77 (0.61, 0. |
| | | | |
| Heterogeneity between groups: P=0.1 GRADE certainty of evidence: Modera | | 0.25 0.5 Favours Iron | 1 2 4 Favours usual care/placebo |
| GRADE certainty of evidence: Modera | te | 0.25 0.5 Favours Iron | Favours usual care/placebo |
| GRADE certainty of evidence: Modera | | 0.25 0.5 | |
| GRADE certainty of evidence: Modera (b) Cardiovascular death Trial | te | 0.25 0.5 Favours Iron | Favours usual care/placebo |
| GRADE certainty of evidence: Modera (b) Cardiovascular death Trial <u>Non-dialysis CKD</u> | te | 0.25 0.5 Favours Iron | Favours usual care/placebo |
| SRADE certainty of evidence: Modera (b) Cardiovascular death Trial <u>Non-dialvsis CKD</u> FAIR-HF | te Active | 0.25 0.5 Favours Iron | Favours usual care/placebo RR (95% Cl) |
| SRADE certainty of evidence: Modera (b) Cardiovascular death Trial <u>Non-dialvsis CKD</u> FAIR-HF AFFIRM-AHF | te Active 4/130 | 0.25 0.5 Favours Iron Control | Favours usual care/placebo RR (95% Cl) 0.72 (0.16, 3. 0.75 (0.49, 1. |
| SRADE certainty of evidence: Modera b) Cardiovascular death frial Non-dialvsis CKD FAIR-HF AFFIRM-AHF The Iron and the Heart Study | 4/130 40/292 0/26 | 0.25 0.5 Favours Iron Control | RR (95% CI) |
| SRADE certainty of evidence: Moderar (b) Cardiovascular death Trial Non-dialysis CKD FAIR-HF AFFIRM-AHF The Iron and the Heart Study Subgroup (I ² = 0.0%, P-heterogeneity=0. | 4/130 40/292 0/26 | 0.25 0.5 Favours Iron Control | RR (95% CI) |
| GRADE certainty of evidence: Modera (b) Cardiovascular death Trial Non-dialysis CKD FAIR-HF AFFIRM-AHF The Iron and the Heart Study Subgroup (I ² = 0.0%, P-heterogeneity=0. Dialysis-requiring CKD | 4/130 40/292 0/26 | 0.25 0.5 Favours Iron Control | Favours usual care/placebo RR (95% Cl) 0.72 (0.16, 3. |
| SRADE certainty of evidence: Modera (b) Cardiovascular death Trial Non-dialvsis CKD FAIR-HF AFFIRM-AHF The Iron and the Heart Study Subgroup (I ² = 0.0%, P-heterogeneity=0. Dialvsis-requiring CKD McIntyre et al. | te Active 4/130 40/292 0/26 .98) | 0.25 0.5 Favours Iron | Favours usual care/placebo RR (95% Cl) 0.72 (0.16, 3. 0.75 (0.49, 1. 1.07 (0.02, 52 0.75 (0.50, 1. |
| SRADE certainty of evidence: Modera (b) Cardiovascular death Trial Non-dialvsis CKD FAIR-HF AFFIRM-AHF The Iron and the Heart Study Subgroup (I ² = 0.0%, P-heterogeneity=0. Dialvsis-requiring CKD McIntyre et al. PIVOTAL | te Active 4/130 40/292 0/26 988 | 0.25 0.5 Favours Iron | Favours usual care/placebo RR (95% Cl) 0.72 (0.16, 3. 0.75 (0.49, 1. 1.07 (0.02, 52 0.75 (0.50, 1. 0.17 (0.01, 4. |
| SRADE certainty of evidence: Modera (b) Cardiovascular death Trial Non-dialvsis CKD FAIR-HF FAIR-HF The Iron and the Heart Study Subgroup (I ² = 0.0%, P-heterogeneity=0. Dialvsis-requiring CKD Weintyre et al. PIVOTAL WAINTAIN IRON | te Active 4/130 40/292 0/26 98) 0/42 91/1093 3/39 | 0.25 0.5 Favours Iron | Favours usual care/placebo RR (95% Cl) 0.72 (0.16, 3, 0.75 (0.49, 1, 1.07 (0.02, 52 0.75 (0.50, 1, 0.17 (0.01, 4, 0.87 (0.66, 1, 0.15 (0.01, 2, |
| SRADE certainty of evidence: Moderar (b) Cardiovascular death Trial Non-dialvsis CKD FAIR-HF AFFIRM-AHF The Iron and the Heart Study Subgroup (I ² = 0.0%, P-heterogeneity=0. Dialvsis-requiring CKD McIntyre et al. PIVOTAL WAINTAIN IRON Subgroup (I ² = 0.0%, P-heterogeneity=0. | te Active 4/130 40/292 0/26 .98) 0/42 91/1093 3/39 .30) | 0.25 0.5 Favours Iron | Favours usual care/placebo RR (95% Cl) 0.72 (0.16, 3. 0.75 (0.49, 1. 1.07 (0.02, 52 0.75 (0.50, 1. 0.17 (0.01, 4. 0.87 (0.66, 1. |
| GRADE certainty of evidence: Modera | te Active 4/130 40/292 0/26 .98) 0/42 91/1093 3/39 .30) 73) | 0.25 0.5 Favours Iron | RR (95% Cl) 0.72 (0.16, 3) 0.75 (0.49, 1) 1.07 (0.02, 52) 0.75 (0.50, 1) 0.17 (0.01, 4) 0.15 (0.01, 2) 0.65 (0.26, 1) |

*First and recurrent hospitalisation for heart failure. CKD: chronic kidney disease; RR: relative risk; CI: confidence interval. GRADE: Grading of Recommendations, Assessment, Development and Evaluation.

Figure 3. Effects of iron therapies vs. usual care or placebo on (A) myocardial infarction, (B) stroke and (C) kidney failure in people with CKD.



CKD: chronic kidney disease; RR: relative risk; CI: confidence interval. GRADE: Grading of Recommendations, Assessment, Development and Evaluation.

Figure 4. Effect of iron therapies vs. usual care or placebo on all-cause mortality in people with CKD.

| Trial | Active | Control | | RR (95% CI) |
|--------------------------------------------|---------------|----------|-----------------------------------------------------|-------------------|
| | | | | |
| Non-dialysis CKD | 5/100 | 0/70 | | |
| FAIR-HF | 5/130 | 3/73 | | 0.91 (0.22, 3.79) |
| Charytan et al. (non-dialysis) | 0/204 | 0/212 | | 1.04 (0.02, 52.12 |
| Yokoyama et al. | 1/60 | 0/30 | | 1.52 (0.06, 36.34 |
| Fishbane et al. (2017) | 2/117 | 0/116 | | 4.96 (0.24, 102.1 |
| Block et al. (2019) | 2/133 | 1/66 | | 0.99 (0.09, 10.75 |
| AFFIRM-AHF | 53/293 | 57/289 | | 0.92 (0.65, 1.28) |
| AEGIS-CKD | 1/111 | 1/56 | • <u>•</u> •••••••••••••••••••••••••••••••••• | 0.50 (0.03, 7.92) |
| The Iron and the Heart Study | 0/26 | 0/28 | | 1.07 (0.02, 52.26 |
| Subgroup (I ² = 0.0%, P-heterog | geneity=0.98) | | 4 | 0.93 (0.68, 1.28) |
| Dialysis-requiring CKD | | | | |
| Besarab et al. | 1/23 | 2/19 | < | 0.41 (0.04, 4.21) |
| DRIVE | 1/66 | 1/66 | | 1.00 (0.06, 15.65 |
| McIntyre et al. | 0/42 | 1/21 | <u>← -</u> | 0.17 (0.01, 4.02) |
| Charytan et al. (dialysis) | 0/50 | 2/47 | <u>← = </u> | 0.19 (0.01, 3.82) |
| Floege et al. | 7/391 | 7/267 | | 0.68 (0.24, 1.92) |
| CRUISE 1 and 2 | 12/292 | 5/296 | +- - | 2.43 (0.87, 6.82) |
| Lewis et al. | 13/292 | 8/149 | | 0.83 (0.35, 1.96) |
| PRIME | 2/54 | 3/49 | | 0.60 (0.11, 3.47) |
| Koiwa et al. | 0/100 | 0/92 | <→ | 0.92 (0.02, 45.94 |
| PIVOTAL | 246/1093 | 269/1048 | — | 0.84 (0.71, 1.00) |
| Susantitaphong et al. | 7/100 | 7/100 | | 1.00 (0.36, 2.75) |
| van den Oever et al. | 15/94 | 24/91 | | 0.59 (0.31, 1.10) |
| MAINTAIN IRON | 3/39 | 3/40 | | 1.03 (0.22, 4.78) |
| Subgroup (I ² = 0.0%, P-heterog | geneity=0.78) | | \diamond | 0.83 (0.71, 0.97) |
| Overall (I ² = 0.0%, P-heteroge | eneity= 0.97) | | \ | 0.85 (0.74, 0.98) |
| Heterogeneity between group | ps: P=0.52 | | | |
| GRADE certainty of evidence | e: Low | | 0.25 0.5 1 2 4 Favours iron Favours usual care/p | |

CKD: chronic kidney disease; RR: relative risk; CI: confidence interval. GRADE: Grading of Recommendations, Assessment, Development and Evaluation.

Figure 5. Effect of iron therapies vs. usual care or placebo on serious adverse events in people with CKD.

| Serious adverse events | | | | | | |
|----------------------------------------------|--------------|----------|---------------------------------------|------------------|--|--|
| Trial | Active | Control | | RR (95% CI) | | |
| Non-dialysis CKD | | | | | | |
| Charytan et al. (non-dialysis) | 6/204 | 20/212 | | 0.31 (0.13, 0.76 | | |
| Yokoyama et al. | 8/60 | 3/30 | | 1.33 (0.38, 4.67 | | |
| Block et al. (2015) | 4/75 | 7/73 | | 0.56 (0.17, 1.82 | | |
| Fishbane et al. (2017) | 14/117 | 13/116 | + | 1.07 (0.52, 2.17 | | |
| Block et al. (2019) | 24/133 | 21/66 | — — — | 0.57 (0.34, 0.94 | | |
| AFFIRM-AHF | 143/293 | 160/289 | _ | 0.88 (0.75, 1.03 | | |
| AEGIS-CKD | 23/111 | 12/56 | + | 0.97 (0.52, 1.80 | | |
| The Iron and the Heart Study | 0/26 | 0/28 | · | 1.07 (0.02, 52.2 | | |
| Subgroup (I ² = 22.8%, P-heteroge | eneity=0.25) | | \diamond | 0.79 (0.61, 1.00 | | |
| Dialysis-requiring CKD | | | | | | |
| DRIVE | 9/66 | 9/66 | | 1.00 (0.42, 2.36 | | |
| McIntyre et al. | 5/42 | 5/21 | | 0.50 (0.16, 1.54 | | |
| Charytan et al. (dialysis) | 3/50 | 3/47 | | 0.94 (0.20, 4.43 | | |
| Lewis et al. | 121/292 | 76/149 | | 0.81 (0.66, 1.00 | | |
| Floege et al. | 78/391 | 52/267 | -#- | 1.02 (0.75, 1.40 | | |
| PRIME | 18/54 | 20/49 | - <u></u> | 0.82 (0.49, 1.35 | | |
| CRUISE 1 and 2 | 142/292 | 166/296 | | 0.87 (0.74, 1.01 | | |
| Koiwa et al. | 2/108 | 1/105 | | 1.94 (0.18, 21.1 | | |
| PIVOTAL | 709/1093 | 671/1048 | - | 1.01 (0.95, 1.08 | | |
| Susantitaphong et al. | 7/100 | 7/100 | | 1.00 (0.36, 2.75 | | |
| Subgroup (I ² = 0.0%, P-heteroger | neity=0.45) | | Ŷ | 0.98 (0.92, 1.03 | | |
| Overall (I ² = 21.7%, P-heteroger | neity= 0.20) | | \$ | 0.90 (0.82, 0.98 | | |
| Heterogeneity between groups | : P=0.09 | | | | | |
| GRADE certainty of evidence: I | Moderate | | | | | |
| | | | 0.25 0.5 1 2 4 | | | |
| | | | Favours iron Favours usual care/place | ebo | | |

CKD: chronic kidney disease; RR: relative risk; CI: confidence interval. GRADE: Grading of Recommendations, Assessment, Development and Evaluation.

REFERENCES

1. Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J. 2020;13(4):613-24.

2. Guedes M, Muenz DG, Zee J, Bieber B, Stengel B, Massy ZA, et al. Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. Journal of the American Society of Nephrology. 2021;32(8):2020-30.

3. Guedes M, Muenz D, Zee J, Lopes MB, Waechter S, Stengel B, et al. Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. Nephrology Dialysis Transplantation. 2021;36(9):1694-703.

4. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020;31(3):456-68.

5. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, Van Veldhuisen DJ, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. European Heart Journal. 2023;44(48):5077-91.

6. Members: ATF, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. 2024;26(1):5-17.

7. Group KDIGOKAW. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012;2:279–335.

8. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease. Circulation. 2021;143(11):1157-72.

9. Beldhuis IE, Lam CS, Testani JM, Voors AA, Van Spall HG, Ter Maaten JM, et al. Evidencebased medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145(9):693-712.

10. Gutiérrez OM. Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease. Kidney International Reports. 2021;6(9):2261-9.

11. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of clinical epidemiology. 2011;64(4):380-2.

12. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2009;361(25):2436-48.

13. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022;400(10369):2199-209.

14. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. New England Journal of Medicine. 2023;389(11):975-86.

15. Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet. 2020;396(10266):1895-904.

16. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency[†]. Eur Heart J. 2015;36(11):657-68.

17. Anumas S, Chatkrailert A, Tantiyavarong P. Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial). Scientific Reports. 2023;13(1):1287.

 Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11(3):530-8.
Bhandari S, Allgar V, Lamplugh A, Macdougall I, Kalra PA. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol. 2021;22(1):115.

20. Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M, et al. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. J Am Soc Nephrol. 2019;30(8):1495-504.

21. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis. 2015;65(5):728-36.

22. Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013;28(4):953-64.

23. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18(3):975-84.

24. Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, et al. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. J Am Soc Nephrol. 2017;28(6):1851-8.

25. Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guss CD, et al. Ferric pyrophosphate citrate (Triferic[™]) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015;30(12):2019-26.

26. Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037-46.

27. Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 2015;88(5):1187-94.

28. Iguchi A, Yamamoto S, Yamazaki M, Tasaki K, Suzuki Y, Kazama JJ, et al. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency. Clin Exp Nephrol. 2018;22(4):789-96.

29. Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study. Nephrology (Carlton). 2017;22(4):293-300.

30. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. New England Journal of Medicine. 2019;380(5):447-58.

31. McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):401-9.

32. Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis. 2021;78(6):846-56.e1.

33. Susantitaphong P, Siribumrungwong M, Takkavatakarn K, Chongthanakorn K, Lieusuwan S, Katavetin P, et al. Effect of Maintenance Intravenous Iron Treatment on Erythropoietin Dose in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial. Can J Kidney Health Dis. 2020;7:2054358120933397.

34. Umanath K, Greco B, Jalal DI, McFadden M, Sika M, Koury MJ, et al. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis . Clin Nephrol. 2017;87 (2017)(3):124-33.

35. van den Oever FJ, Heetman-Meijer CFM, Birnie E, Vasbinder EC, Swart EL, Schrama YC. A pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial. Pharmacol Res Perspect. 2020;8(4):e00628.

36. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9(3):543-52.

37. Zununi Vahed S, Ahmadian E, Hejazian SM, Esmaeili S, Farnood F. The Impact of Intravenous Iron Supplementation on Hematinic Parameters and Erythropoietin Requirements in Hemodialysis Patients. Adv Ther. 2021;38(8):4413-24.

38. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88(4):905-14.

39. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445-54.

40. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003;51:170-4.

41. Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31(4):646-55.

42. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075-84.

43. McMahon LP, Kent AB, Kerr PG, Healy H, Irish AB, Cooper B, et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrol Dial Transplant. 2010;25(3):920-6.

44. Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015;30(4):645-52.

45. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846-56.

46. Agarwal R, Leehey DJ, Olsen SM, Dahl NV. Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(1):114-21.

47. Barraclough KA, Brown F, Hawley CM, Leary D, Noble E, Campbell SB, et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant. 2012;27(11):4146-53.

48. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021;36(1):111-20.

49. Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer[®]) compared with iron sucrose (Venofer[®]) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30(9):1577-89.

50. Bielesz B, Lorenz M, Monteforte R, Prikoszovich T, Gabriel M, Wolzt M, et al. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021;16(10):1512-21.

51. Kassianides X, Gordon A, Sturmey R, Bhandari S. The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study. Kidney Res Clin Pract. 2021;40(1):89-98.

52. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant. 2001;16(6):1239-44.

53. Macdougall IC, Strauss WE, Dahl NV, Bernard K, Li Z. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial . Clin Nephrol. 2019;91(4):237-45.

54. Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833-42.

55. Pergola PE, Belo D, Crawford P, Moustafa M, Luo W, Goldfarb-Rumyantzev A, et al. Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease. Am J Nephrol. 2021;52(7):572-81.

56. Sood V, Kamboj K, Bhatia P, Sharma V, Kundu M, Ghosh A, et al. A randomized trial of once daily versus twice daily dosing of oral iron in CKD. Sci Rep. 2023;13(1):141.

57. Mark PB, Mangion K, Rankin AJ, Rutherford E, Lang NN, Petrie MC, et al. Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. Clinical Kidney Journal. 2022;15(12):2186-99.

58. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine. 2019;380(5):447-58.

59. O'Lone E, Howell M, Viecelli AK, Craig JC, Tong A, Sautenet B, et al. Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation. 2020;35(10):1761-9.

60. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, De Zeeuw D, Eckardt K-U, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine. 2009;361(21):2019-32.

61. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. New England Journal of Medicine. 2006;355(20):2085-98.

62. Macdougall IC, Bhandari S, White C, Anker SD, Farrington K, Kalra PA, et al. Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. Journal of the American Society of Nephrology: JASN. 2020;31(5):1118.

63. Wolf M, Auerbach M, Kalra PA, Glaspy J, Thomsen LL, Bhandari S. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. Am J Hematol. 2021;96(1):E11-e5.

64. Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M, et al. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. Journal of the American Society of Nephrology. 2019;30(8):1495-504.